Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Common Comorbid Condition of Patients With Autism Spectrum Disorder and Pharmacotherapy for Patients With Autism Spectrum Disorder

  • Un Sun Chung (Department of Psychiatry, Kyungpook National University, School of Medicine) ;
  • Ji-Hoon Kim (Department of Psychiatry, Pusan National University, School of Medicine)
  • Received : 2023.01.30
  • Accepted : 2023.12.18
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

This article describes common comorbid condtion of the autism spectrum disorder (ASD) and recommends treatment guidelines of pharmacotherapy for patients with ASD. More than 95% of people with ASD have at least one additional disorder and guidelines how to evaluate and treat comorbid conditions in patients with ASD and 7 recommendations for treatment with medication for ASD.

Keywords

Acknowledgement

This study was supported by the Ministry of Health and Welfare, Behavior and Development Center, and the Headquarter of the National Autism and Developmental Disorder Centers.

References

  1. American Psychiatric Association. What is autism spectrum disorder? [Internet]. Washington, DC: American Psychiatric Association [cited 2021 Aug 31]. Available from: https://www.psychiatry.org/patients-families/autism/what-is-autism-spectrum-disorder. 
  2. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry 2019;6:819-829.  https://doi.org/10.1016/S2215-0366(19)30289-5
  3. Rosen TE, Mazefsky CA, Vasa RA, Lerner MD. Co-occurring psychiatric conditions in autism spectrum disorder. Int Rev Psychiatry 2018;30:40-61.  https://doi.org/10.1080/09540261.2018.1450229
  4. Soke GN, Maenner MJ, Christensen D, Kurzius-Spencer M, Schieve LA. Prevalence of co-occurring medical and behavioral conditions/symptoms among 4- and 8-year-old children with autism spectrum disorder in selected areas of the United States in 2010. J Autism Dev Disord 2018;48:2663-2676.  https://doi.org/10.1007/s10803-018-3521-1
  5. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2014;53:237-257.  https://doi.org/10.1016/j.jaac.2013.10.013
  6. Mason D, Ingham B, Urbanowicz A, Michael C, Birtles H, Woodbury-Smith M, et al. A systematic review of what barriers and facilitators prevent and enable physical healthcare services access for autistic adults. J Autism Dev Disord 2019;49:3387-3400.  https://doi.org/10.1007/s10803-019-04049-2
  7. Fuentes J, Hervas A, Howlin P; ESCAP ASD Working Party. ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry 2021;30:961-984.  https://doi.org/10.1007/s00787-020-01587-4
  8. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 2006;36:849-861.  https://doi.org/10.1007/s10803-006-0123-0
  9. New York State Department of Health. Clinical practice guideline on assessment and intervention services for young children with autism spectrum disorders (ASD): 2017 update [Internet]. Albany, NY: New York State Department of Health [cited 2017 Oct 31]. Available from: https://www.health.ny.gov/publications/20152.pdf. 
  10. Christensen DL, Braun KVN, Baio J, Bilder D, Charles J, Constantino JN, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ 2018;65:1-23.  https://doi.org/10.15585/mmwr.ss6513a1
  11. National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: support and management [Internet]. London: National Institute for Health and Care Excellence [cited 2020 Nov 20]. Available from: https://www.nice.org.uk/guidance/cg170. 
  12. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-327.  https://doi.org/10.1097/00004714-199210000-00005
  13. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82. 
  14. Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 2015;172:1197-1206.  https://doi.org/10.1176/appi.ajp.2015.15010055
  15. U.S. Food and Drug Administration. Highlights of prescribing information: Risperidone. Silver Spring, MD: U.S. Food and Drug Administration [cited 2020 May 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020272s082,020588s070,021444s056lbl.pdf. 
  16. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs: Aripiprazole (products on NDA 021436) [Internet]. Silver Spring, MD: U.S. Food and Drug Administration [cited 2020 May 5]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021436. 
  17. Kim HW, Park EJ, Kim JH, Boon-Yasidhi V, Tarugsa J, Reyes A, et al. Aripiprazole for irritability in asian children and adolescents with autistic disorder: a 12-week, multinational, multicenter, prospective open-label study. J Child Adolesc Psychopharmacol 2018;28:402-408.  https://doi.org/10.1089/cap.2017.0152
  18. Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry Hum Dev 2017;48:796-806.  https://doi.org/10.1007/s10578-016-0704-x
  19. Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 2013;43:1773-1783.  https://doi.org/10.1007/s10803-012-1723-5
  20. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-1119.  https://doi.org/10.1097/CHI.0b013e3181b76658
  21. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-1148.  https://doi.org/10.1176/appi.ajp.162.6.1142
  22. European Medicines Agency. Haloperidol [Internet]. Amsterdam: European Medicines Agency [cited 2020 May 5]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/haldolassociated-names. 
  23. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-692.  https://doi.org/10.1089/cap.2005.15.682
  24. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35:990-998.  https://doi.org/10.1038/npp.2009.202
  25. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013;8:CD004677. 
  26. Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry 2018;30:78-95.  https://doi.org/10.1080/09540261.2018.1458706
  27. Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012;51:733-741.  https://doi.org/10.1016/j.jaac.2012.04.011
  28. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res 2012;21:700-709.  https://doi.org/10.1111/j.1365-2869.2012.01021.x
  29. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274.  https://doi.org/10.1001/archpsyc.62.11.1266
  30. Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev 2017;11:CD011144. 
  31. Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A 2017;114:8119-8124.  https://doi.org/10.1073/pnas.1705521114
  32. Bernaerts S, Boets B, Bosmans G, Steyaert J, Alaerts K. Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Mol Autism 2020;11:6. 
  33. Ooi YP, Weng SJ, Kossowsky J, Gerger H, Sung M. Oxytocin and autism spectrum disorders: a systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry 2017;50:5-13.  https://doi.org/10.1055/s-0042-109400
  34. Dean OM, Gray KM, Villagonzalo KA, Dodd S, Mohebbi M, Vick T, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry 2017;51:241-249.  https://doi.org/10.1177/0004867416652735
  35. Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism 2016;7:26. 
  36. Minshawi NF, Wink LK, Shaffer R, Plawecki MH, Posey DJ, Liu H, et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Mol Autism 2016;7:2. 
  37. Aman MG, Findling RL, Hardan AY, Hendren RL, Melmed RD, Kehinde-Nelson O, et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and openlabel extension. J Child Adolesc Psychopharmacol 2017;27:403-412.  https://doi.org/10.1089/cap.2015.0146
  38. Centers for Disease Control and Prevention. Autism spectrum disorder (ASD). Recommendations and guidelines [Internet]. Atlanta, GA: Centers for Disease Control and Prevention [cited 2021 Nov 20]. Available from: https://www.cdc.gov/ncbddd/autism/hcp-recommendations.html. 
  39. Fombonne E, Goin-Kochel RP, O'Roak BJ; SPARK Consortium. Beliefs in vaccine as causes of autism among SPARK cohort caregivers. Vaccine 2020;38:1794-1803.  https://doi.org/10.1016/j.vaccine.2019.12.026
  40. National Institute for Health and Care Excellence. Autism: The management and support of children and young people on the autism spectrum: NICE guideline DRAFT [Internet]. London: National Institute for Health and Care Excellence [cited 2016 May 24]. Available from: https://www.nice.org.uk/guidance/cg170/documents/autism-management-of-autism-in-children-and-young-people-nice-version2. 
  41. National Institute for Health and Care Excellence. Autism spectrum disorder in adults: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence [cited 2021 Nov 20]. Available from: https://www.nice.org.uk/guidance/cg142. 
  42. Williams KJ, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;2012:CD003495. 
  43. Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006;36:901-909.  https://doi.org/10.1007/s10803-006-0131-0
  44. Hyman SL, Levy SE. Dietary, complementary and alternative therapies. In: Reichow B, Doehring P, Cicchetti DV, Volkmar FR, editors. Evidence-based practices and treatments for children with autism. 1st ed. New York: Springer;2011. p.275-293. 
  45. Reichow B, Doehring P, Cicchetti DV, Volkmar FR. Evidence-based practices and treatments for children with autism. 1st ed. New York: Springer;2011.